2013
DOI: 10.4161/cbt.22626
|View full text |Cite
|
Sign up to set email alerts
|

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 33 publications
(30 reference statements)
0
10
0
Order By: Relevance
“…Consequently, early screening for elevated sHER2 ECD levels may improve the detection of metastatic breast cancer. Surprisingly, Kontani et al [42], found elevated sHER2 ECD levels in seven patients (22.6%) with metastatic or recurrent HER2− breast cancers. This might be explained if the tumors were derived from HER2-overexpressing cancer cells in the primary tumor in which HER2− cells were dominant.…”
Section: The Prevalence Of Sher2 Ecd In Breast Cancer and Its Correlamentioning
confidence: 94%
See 1 more Smart Citation
“…Consequently, early screening for elevated sHER2 ECD levels may improve the detection of metastatic breast cancer. Surprisingly, Kontani et al [42], found elevated sHER2 ECD levels in seven patients (22.6%) with metastatic or recurrent HER2− breast cancers. This might be explained if the tumors were derived from HER2-overexpressing cancer cells in the primary tumor in which HER2− cells were dominant.…”
Section: The Prevalence Of Sher2 Ecd In Breast Cancer and Its Correlamentioning
confidence: 94%
“…In another recent study of 2862 cases of stage I-III primary breast cancer patients, 24% were found to be tHER2+, but only 15% of these tHER2+ patients had elevated sHER2 ECD levels [41]. Another study [42] found 23.5% of patients with tHER2+ early-stage breast cancer had elevated sHER2 ECD levels (>15 ng/ml). A later study [43] also showed that the levels of sHER2 ECD did not correlate with the level of HER2 overexpression, whether borderline (2+) or positive (3+) on the IHC testing scale described above.…”
Section: Do Sher2 Ecd Levels Correlate With Tissue Her2 Levels?mentioning
confidence: 95%
“…The high percentage of elevated serum HER2 levels among the patients with tissue HER2-positive tumors (43%), even though the blood samples often were taken after primary treatment, suggests a potential use of serum HER2 in patient follow-up during and after treatment. Comparable numbers (23.5% of the patients with tissue HER2-positive versus 8.7% of the patients with tissue HER2-negative tumors) were published by Kontani et al 30 in a study with 252 patients using the ADVIVA CLIA assay, and they suggested that HER2 may be a useful biomarker for detecting breast cancer recurrence. The higher percentage of patients with elevated HER2 in our study compared to Kontani et al may be explained by different assay antibodies and/ or different cut-off values.…”
Section: Discussionmentioning
confidence: 90%
“…Moreover, these methods can only determine the HER2 status at the time of diagnosis, and the HER2 status of tumor samples in patients with recurrent or metastatic breast cancer cannot always be determined. It would be useful to monitor patients during follow-up to determine wheth- er they are responding to trastuzumab therapy [22] . RTqPCR is a powerful technique to confirm HER2 gene expression differences or measure transcript abundance.…”
Section: Discussionmentioning
confidence: 99%